Remedy Robotics awards HYD A$3.4M Surgical Robotics Contract

• HYD awarded A$3.4M contract by Remedy Robotics
• Contract involves developing software and electronics for N1 robotic platform
• Expected to generate revenue in FY2027, over 50% of HYD's market cap

HYDRIX Limited (ASX: HYD) has secured a significant A$3.4 million engineering development contract with US-based Remedy Robotics. This contract involves the development of safety-critical software and embedded electronics for Remedy's next-generation N1 robotic platform for endovascular intervention. The contract reinforces HYD's position as a specialist engineering partner in advanced medical robotics, a rapidly growing segment of the global medical technology industry. Based on the agreed scope of work, to be undertaken on a time-and-materials basis, HYD expects the contract to generate approximately A$3.4 million in revenue. Revenue will be recognised progressively in FY2027 and is expected to be over 50% of HYD's current market capitalisation.

Expected A$3.4M revenue in FY2027

The contract is expected to significantly expand HYD's engineering support for Remedy's N1 system, accelerating platform maturity for future clinical studies.